MedTrace Logo

Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

NCT04082507 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-09-09

No results posted yet for this study

Summary

The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.

Conditions

  • Placenta Accreta

Interventions

DIAGNOSTIC_TEST

Serum alpha-fetoproteine

Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .

Sponsors & Collaborators

  • rasha medhat abdul-hady

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-08-30
Completion
2019-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04082507 on ClinicalTrials.gov